To sum up, our study shows that ISP-I, the active component of CFDA-approved macrolide antibiotic carrimycin, induces apoptosis and G2/M arrest through ROS-mediated PI3K/AKT signaling pathway inhibition, ultimately leading to NSCLC cell death. Here, PIK3CB is linked to non-small cell lung carcinoma.